Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML.

In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subtypes of AML.

DiNardo focuses on three specific subgroups: patients with IDH1/2 mutations; patients with FLT3 mutations; and patients with TP53 mutations. After talking about the promising results reported at ASH, DiNardo pointed out that unmet needs still exist, especially for patients with TP53 mutations.